Allergan Steers Bimatoprost Eyelash Enhancer To Drug, Not Cosmetic, Market
This article was originally published in The Rose Sheet
Executive Summary
Allergan says it will file a new drug application with FDA later this year for the eyelash growth stimulant bimatoprost, the key ingredient in cosmetic offerings that caught the drug company's - and FDA's - watchful eye earlier this year
You may also be interested in...
Allergan Adds To Growth Areas With Acquisition Of Eye-Disease Compounds
Deal with UK’s Asterand nets preclinical prostaglandin receptor agonists with potential in glaucoma, other eye conditions.
Jan Marini Ceases Eyelash Product Sales Due To Allergan Suit, FDA Threat
Jan Marini Skin Research (JMSR) is suspending sales of its two Age Intervention eyelash products in the U.S. - citing an uncertain regulatory environment and the daunting prospect of litigation - and focusing on its core skin-care line and opportunities abroad
Jan Marini Focused On Damage Control Following FDA Seizure Of Eyelash Item
Jan Marini issued a statement Nov. 16 stressing that its Age Intervention Eyelash product has not been manufactured or distributed since September of last year, in response to a release from FDA announcing seizure of the "potentially harmful" product